Filing Details
- Accession Number:
- 0000899243-20-018398
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-02 20:56:47
- Reporting Period:
- 2020-07-02
- Accepted Time:
- 2020-07-02 20:56:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1631574 | Wave Life Sciences Ltd. | WVE | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1657710 | Paul Bolno | C/O Wave Life Sciences Ltd., 733 Concord Ave. Cambridge MA 02138 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Disposition | 2020-07-02 | 4,509 | $10.82 | 315,249 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-07-02 | 43,068 | $10.26 | 272,181 | No | 4 | S | Direct | |
| Ordinary Shares | Acquisiton | 2020-07-02 | 100,000 | $2.48 | 372,181 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2020-07-02 | 4,079 | $10.91 | 368,102 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-07-02 | 95,921 | $10.27 | 272,181 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Share Option (right to buy) | Disposition | 2020-07-02 | 100,000 | $0.00 | 100,000 | $2.48 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 222,778 | 2025-03-10 | No | 4 | M | Direct |
Footnotes
- Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- These share options are fully vested.
Billionaire Hedge Funds
